CON – Cynthia Seow MBBS (Hons), MSc, FRACP
Division of Gastroenterology and Hepatology
Departments of Medicine and Community Health Sciences
University of Calgary
Sunday, November 21, 2021
10:00 am - 10:30 am
Debate: Is Anti-TNF the first drug of choice in individuals with moderate to severe IBD?
Given the ever increasing armamentarium of therapies for the management of IBD, clinicians are faced with the dilemma as to which is the drug of choice in individuals with moderate to severe UC and CD. In this session, the presenters will debate the topic "Is anti-TNF the first drug of choice in individuals with moderate to severe IBD?" and provide data on the safety and efficacy of the major biologic classes e.g. anti-TNFs, anti-integrins and anti-IL12/23.
Dr. Cynthia Seow completed medical school, internal medicine and gastroenterology training in Australia, then undertook a 2 year clinical research fellowship in Inflammatory Bowel Disease (IBD) at Mount Sinai Hospital concurrent with a Masters in Clinical Epidemiology at the University of Toronto. She is currently Associate Professor in the Cumming School of Medicine at the University of Calgary. Dr. Seow’s clinical and research practice are intertwined, focussing on special populations across the life cycle, including individuals transitioning from the pediatric to adult IBD service, individuals with sexual health concerns and women contemplating pregnancy or who are currently pregnant. Other interests include optimizing therapy by evaluating pharmacokinetics of biologic therapies and health prevention strategies including vaccination and adherence to medications. She supervises graduate students and is interested in mentoring junior faculty, having recently been appointed chair of the national Future Leaders in IBD (FLIBD) group.